Navigation Links
Andrew Love Joins The Female Health Company Board of Directors
Date:5/14/2013

CHICAGO, May 14, 2013 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO - News), which manufactures and markets the FC2 Female Condom, today announced that it has named Andrew S. Love to be a member of its Board of Directors. 

(Logo: http://photos.prnewswire.com/prnh/20120712/MM39764LOGO)

Mr. Love is Chairman of Love Savings Holding Company, the holding company of Heartland Bank, headquartered in St. Louis.  The Love Companies have been active in real estate, banking and finance since 1875.  Mr. Love has more than 40 years of experience in the investment, banking and real estate communities.  Previously, Mr. Love was a partner at the law firm Bryan Cave, LLP.  

Mr. Love has been a long time investor in, and supporter of, The Female Health Company. Mr. Love was one of the original investors in the Phoenix Limited Partnership whose general partner identified the female condom as an investment opportunity, which ultimately resulted in the creation of The Female Health Company. 

Mr. Love holds an AB degree from Harvard College and an LLB degree from the Harvard Law School.  Mr. Love has served as a board member for many charitable organizations, including the St. Louis Symphony Society, St. Louis Country Day School, St. Louis Repertory Theatre, the Center for Plant Conservation, Webster University, and the Edward K. Love Conservation Foundation.

O.B. Parrish , Chairman and CEO of The Female Health Company said: "We are delighted to have Andy Love as a member on our Board."

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 139 other countries globally.  The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process.  The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:

The statements in this release which are not historical fact are "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update any forward-looking statements contained in this release as a result of new information or future events, developments or circumstances. Such forward-looking statements are inherently subject to known and unknown risks and uncertainties.  The Company's actual results and future developments could differ materially from the results or developments expressed in, or implied by, these forward-looking statements.  Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to, the following:  product demand and market acceptance; competition in the Company's markets and the risk of new competitors and new competitive product introductions; the Company's reliance on its international partners in the consumer sector and on the level of spending on the female condom by country governments, global donors and other public health organizations in the global public sector; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company's production capacity, efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings, including the Company's Form 10-K for the fiscal year ended September 30, 2012.  Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.


'/>"/>
SOURCE The Female Health Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Andrew Technologies Obtains Patent for Visceral Lipectomy Application from USPTO
2. Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
3. GSK CEO Sir Andrew Witty Interviewed on Q2 2012 Results
4. Canadas Sunnybrook Health Sciences Centre Joins Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy
5. Former FDA Official Tim Cote Joins Emmaus Medical as Regulatory Advisor
6. Dr. William McGuire, Former UnitedHealth Group CEO, Joins Rebiotix Inc. Board of Directors
7. Peter Dinklage Joins Cruelty Free International to Call for US ban on Animal Tests for Cosmetics
8. Dr. Emad Rizk Joins Accuray Board of Directors
9. James Lang Joins the NASP Board of Directors
10. ESPN Chief Medical Correspondent Joins Orthopaedic Industry Leaders at OrthoTec 2013
11. Peter W. Schineller Joins Alexza Pharmaceuticals as Senior Vice President and Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):